PD681 - TARGETED INTERVENTION WITH Β-HYDROXY-Β-METHYLBUTYRATE (HMB) ENRICHED ORAL NUTRITION SUPPLEMENT IS ASSOCIATED WITH REDUCED HEALTHCARE RESOURCE USE IN GENERAL AND CANCER OUTPATIENTS
PD681
TARGETED INTERVENTION WITH Β-HYDROXY-Β-METHYLBUTYRATE (HMB) ENRICHED ORAL NUTRITION SUPPLEMENT IS ASSOCIATED WITH REDUCED HEALTHCARE RESOURCE USE IN GENERAL AND CANCER OUTPATIENTS
I. Cornejo-Pareja1,2,3, K. W. Kerr4, M. Ramirez5, M. Camprubi Robles5,*, I. M. Vegas-Aguilar1,2, R. Fernandez-Jimenez1,3,6, M. Amaya-Campos1,2, A. Martinez-Martinez1,2, J. Martinez-Martin7, J. M. Garcia-Almeida1,2,3
1Virgen de la Victoria Hospital, 2Instituto de Investigacion Biomedica de Malaga, 3University of Malaga, Malaga, Spain, 4Abbott Nutrition, Columbus, United States, 5Abbott Nutrition, Granada, 6Instituto de Investigacio Biomedica de Malaga, 7Financial Control, Virgen de la Victoria Hospital, Malaga, Spain
Rationale: Disease-related malnutrition increases healthcare resource use (HCRU). Oral nutrition supplements (ONS) may improve outcomes and reduce healthcare burden. This study compared HCRU before and after daily intake of specialized ONS enriched with β-hydroxy-β-methylbutyrate (HMB-ONS) or standard ONS (S-ONS) within a multimodal nutrition program.
Methods: This retrospective analysis included adult malnourished outpatients (n=283; 177 with cancer). HCRU was assessed up to 12 months before and after program initiation which included diet and exercise recommendations plus HMB-ONS or S-ONS. Difference-in-differences regression adjusted for sex, age, nutritional status, and comorbidities was used to estimate the impact of HMB-ONS versus S-ONS on hospital-recorded health economic outcomes. Statistical significance was set at p<0.05 with Bonferroni–Holm adjustment.
Results: Compared with S-ONS, HMB-ONS use was associated with significantly lower rates of hospitalizations (incidence rate ratio [IRR] 0.5, p=0.011), emergency department (ED) visits (IRR 0.6, p=0.002), and general practice (GP) visits (IRR 0.7, p=0.009), corresponding to reductions of 51%, 39%, and 28%, respectively. In patients with cancer, HMB-ONS was associated with lower rates of hospital admissions (IRR 0.3; p=0.006), ED visits (0.5; p<0.001), GP visits (0.6; p=0.007), and specialist visits (0.8; p=0.038), corresponding to 66%, 54%, 36%, and 18% reductions, respectively. HMB-ONS use was also associated with significantly lower odds of cancer treatment change (OR = 0.117, (p=0.026)).
Conclusion: A multimodal nutrition program including HMB-enriched ONS was associated with reduced HCRU and lower likelihood of cancer treatment disruption.
Disclosure of Interest: I. Cornejo-Pareja: None declared, K. Kerr Shareholder of: Abbott, M. Ramirez Shareholder of: Abbott, M. Camprubi Robles Shareholder of: Abbott, I. M. Vegas-Aguilar: None declared, R. Fernandez-Jimenez: None declared, M. Amaya-Campos: None declared, A. Martinez-Martinez: None declared, J. Martinez-Martin: None declared, J. M. Garcia-Almeida: None declared